Tag Archive for: FDA guidance

The U.S. Food and Drug Administration released new draft guidance that addresses Breakthrough Therapy designation.

In December 2021, the FDA issued draft guidance to lifescience researchers on evaluating EHR and claims data in studies to support regulatory decisions. This new draft guidance covers using real-world data from these sources to support regulatory decisions on both safety and effectiveness.